CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer

DSpace/Manakin Repository

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer

Citable link to this page

 

 
Title: CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
Author: Sengupta, S.; Rojas, R.; Mahadevan, A.; Kasper, E.; Jeyapalan, S.

Note: Order does not necessarily reflect citation order of authors.

Citation: Sengupta, S., R. Rojas, A. Mahadevan, E. Kasper, and S. Jeyapalan. 2015. “CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer.” Oxford Medical Case Reports 2015 (4): 254-257. doi:10.1093/omcr/omv010. http://dx.doi.org/10.1093/omcr/omv010.
Full Text & Related Files:
Abstract: Nervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood–brain barrier, as combination therapy to treat HER2–neu-positive breast cancer with brain metastases.
Published Version: doi:10.1093/omcr/omv010
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664841/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993583
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters